Abstract
The IgMi mouse fails to secrete antibodies or class switch its BCR from IgM. Our study reveals that other cellular compartments, including B‐cell subsets, DC subsets, GC B cells and TFH cells are perturbed in the IgMi mouse, thus presenting important additional considerations when using the mouse to explore the role of secreted antibody.
The current study aims to provide a detailed characterization of IgMi mice by comparing them to their wild type controls to evaluate the use of the IgMi mouse as a novel tool to study B‐cell biology. The IgMi mouse was firstly introduced in 2007 by Waisman et al., as IgHμγ1/μγ1 to address the importance of the cytoplasmic tail in B‐cell development 1, but subsequently became known as the IgMi mouse 2. The IgMi mouse was stated to have a normal B‐cell development, although its B cells only express IgM as a B‐cell receptor on the surface. Moreover, IgMi mice cannot produce any soluble antibodies as all constant regions in the IgH chain have been deleted 1. Thus, as a model to study B‐cell biology, the IgMi mouse offers great potential by virtue of its normal B‐cell development. However, there have been no subsequent publications providing a detailed description of the IgMi mouse under steady state, other than its inability to secrete antibodies.
We corroborate in the current study that IgMi mouse does not secrete any soluble antibodies. Total Ig analysis on the sera using ELISA showed that total Ig was not detected in the sera of IgMi mice with results below the background (Fig. 1A). Furthermore, no IgA antibody was detected in the stool of IgMi mice (Fig. 1B). However, the IgMi mouse showed enlarged secondary lymphoid organs (Fig. 1C) with elevations in B‐cell subsets, including B1a, B1b, transitional and marginal zone B cells (Fig. 1D–H). Natural antibodies, especially IgM, have been considered to play an important role in bridging the innate and adaptive immune systems. Thus, as shown in previous study using the AID−/−μS−/− double mutant mouse 3, the current study revealed that secreted antibodies are important in cell extrinsic processes, controlling B‐cell subsets, such as B1 and MZ B cells. Interestingly, B‐cell development in the IgMi bone marrow was also altered as pre‐B cells and immature B cells were significantly higher, while mature B cells was significantly lower, compared to WT mice (Supplementary 1).
B cells are also known to play a role in modulating the maturation and function of DCs 4, 5. Therefore, we wondered whether the lack of antibodies in IgMi mice would affect the subsets of DC in IgMi secondary lymphoid organs. Interestingly, IgMi mice had significantly lower MLN CD11c+MHCII+ DCs compared to WT littermates. Previous studies showed that the majority of CD11c+MHCII+ DC in the MLN under steady state are CD103+ DCs, including CD103+CD11b+ and CD103+CD11b− 6. Interestingly, IgMi mice had significantly lower numbers of MLN CD103+CD11b+ DCs compared to WT littermates (Fig. 1I–K), while CD103+CD11b− DCs were significantly increased in the spleen (Fig. 1L). Collectively, the data shows that lack of secreted antibody, directly or indirectly, affects B‐cell development in the bone marrow and changes the balance of B cell and DC subsets in secondary lymphoid organs. However, further studies are required to investigate the mechanisms behind those alterations in the IgMi mouse.
In contrast to the AID−/−μS−/− double mutant mouse 3, IgMi mice only showed an increase in the relative percentage and number of germinal centre B cells (Fig. 2A–C), and number of GC in the MLNs (Fig. 2D–E). According to Zhang et al. 7, higher affinity antibodies secreted by B cells reenter the GC and negatively regulate GC formation by binding to follicular dendritic cells and limiting the access of B cells to antigens. Thus, in the absence of soluble antibodies, GC B cells in the IgMi mouse may be undergoing more proliferation and less apoptosis. Our study supports this hypothesis as GC B cells from IgMi mice showed increased proliferation and reduced apoptosis (Supplementary 2). We also investigated plasma cell and plasmablast populations in IgMi MLNs. Levels were very low under steady‐state conditions and we did not see any significant difference between genotype in any tissue (data not shown). In parallel to the increase in GC, the population of T‐follicular helper cells (TFH) in the MLNs of IgMi mice were also significantly increased (Fig. 2F–G). CD4+B220‐CXCR5+PD‐1high cells are known as GC TFH cells due to their ability to enter GCs and maintain stable interactions with B cells. Therefore, the increase in GC seen in IgMi mice correlates well with the increase in GC TFH. Interestingly, we did not see significant differences in CD4 and CD8 T cells in IgMi mice (data not shown).
B‐cell function is not only related to antibody production, but B cells are also able to produce cytokines including IL‐10 8. Due to its pleiotropic activities, IL‐10 is an important regulatory cytokine that is able to act both as an immunostimulator and immunosuppressor. A previous study showed that IL‐10 producing B cells were essential for GC development during malaria infection 9. Thus, the increase in GC cells seen in the IgMi mouse may reflect in part the increased ability by IgMi B cells to make IL‐10 (Fig. 2I–J). However, the mechanisms underlying the ability of IgMi B cells make more IL‐10 remains unknown. Further study is required to investigate whether this phenomenon is related to the lack of antibodies in IgMi mice, and also to address other unanswered questions in B cells biology, such as whether B cells secrete antibody and produce IL‐10 at the same time.
It remains controversial whether antibodies are important in regulating the composition of microbiota or not. Therefore, we also investigated if the lack of antibodies in IgMi mice would change the composition of the gut microbiota compared to their WT littermates. Surprisingly, we found that IgMi mice had a similar gut microbiota composition to their WT littermates based on microbiome analysis using DGGE and real‐time PCR (Supplementary 3). It is possible that, the insignificant difference in gut microbiota between the IgMi mice and WT littermates could be related to maternal immunity 10, however, although both genotypes were breast‐fed by a heterozygous mother, flow cytometric analyses of faecal IgA failed to reveal the presence of any antibody in the IgMi mouse (Fig. 1B). Furthermore, in keeping with the absence of any differences in the gut microbiota in IgMi and WT mice, there were no significant differences in expression levels of IFN‐γ and IL‐17 in the gut in IgMi mice compared to WT littermates (Supplementary 4).
In conclusion, the IgMi mouse represents a powerful model system which, in combination with other B‐cell transgenic mice, can be used to investigate the biology of B cells. However, it is important to be aware that steady‐state differences beyond lack of antibodies exist including differences in B‐cell subsets, B‐cell propensity to make IL‐10, dendritic cell subsets, germinal centers, and T‐follicular helper cells.
Conflict of interest
The authors declare no commercial or financial conflict of interest.
Supporting information
Acknowledgments
This study was funded by the Indonesian endowment fund for education. The work was also supported by the Flow cytometry (Gareth Howell), and Histology at the University of Manchester.
The copyright line for this article was changed on 5 September 2019 after original online publication.
Contributor Information
Rinal Sahputra, Email: rinal.sahputra@manchester.ac.uk.
Kathryn J Else, Email: kathryn.j.else@manchester.ac.uk.
References
- 1. Waisman, A. et al., J. Exp. Med. 2007. 204: 747–758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Waisman, A. et al., Med. Micro. Immunol. 2008. 197: 145–149. [DOI] [PubMed] [Google Scholar]
- 3. Lino, A. C. et al., BLOOD 2013. 122: 209–218. [DOI] [PubMed] [Google Scholar]
- 4. Moulin, V. et al., J. Exp. Med. 2000. 192: 475–482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Ziętara, N. et al., Proc. Natl. Acad. Sci. 2013. 110: 2282–2287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Cerovic, V. et al., Mucosal Immunol. 2013. 6: 104. [DOI] [PubMed] [Google Scholar]
- 7. Zhang, Y. et al., J. Exp. Med. 2013. 210: 457–464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. O'Garra, A. et al., Int. Immunol. 1990. 2: 821–832. [DOI] [PubMed] [Google Scholar]
- 9. Guthmiller, J. J. et al., J. Immunol. 2017. 198: 617–622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Yoshioka, H. et al., Pediatrics 1983. 72: 317–321. [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.